M
Maxine X. Patel
Researcher at King's College London
Publications - 72
Citations - 4190
Maxine X. Patel is an academic researcher from King's College London. The author has contributed to research in topics: Therapeutic drug monitoring & Antipsychotic. The author has an hindex of 30, co-authored 71 publications receiving 3560 citations. Previous affiliations of Maxine X. Patel include South London and Maudsley NHS Foundation Trust & University of Southampton.
Papers
More filters
Journal ArticleDOI
A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
TL;DR: Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds, and clozapine and olanzapine were associated with more favorable outcomes.
Journal ArticleDOI
Challenges in recruitment of research participants
TL;DR: Key issues are: early consideration of the impact of study design on the recruitment process; the participant's perspective; close collaboration with colleagues; the investigator’s good interpersonal, communication and organisational skills; and feedback to collaborators, associated clinicians and participants.
Journal ArticleDOI
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
TL;DR: This method for determining antipsychotic dose equivalence entails an operationalized and evidence-based approach that can be applied to the various antipsychoses and is applicable to specific populations such as first-episode or refractory patients.
Journal ArticleDOI
Depersonalisation disorder: clinical features of 204 cases.
Dawn Baker,Elaine Hunter,Emma Lawrence,Nick Medford,Maxine X. Patel,Carl Senior,Mauricio Sierra,Michelle V. Lambert,Mary L. Phillips,Anthony S. David +9 more
TL;DR: Depersonalisation disorder is a recognisable clinical entity but appears to have significant comorbidity with anxiety and depression and research into its aetiology and treatment is warranted.
Journal ArticleDOI
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Stephen Cooper,Gavin P. Reynolds,Thomas R. E. Barnes,Elizabeth England,Peter M. Haddad,Adrian H. Heald,Richard I. G. Holt,Anne Lingford-Hughes,David Osborn,Olga O McGowan,Maxine X. Patel,Carol Paton,P. Reid,David Shiers,Jo Smith +14 more
TL;DR: These guidelines review issues surrounding monitoring of physical health risk factors and make recommendations about an appropriate approach to interventions for people experiencing weight gain when taking antipsychotic medications.